Current Surgical Management Strategies for Colorectal Cancer Liver Metastases
Open accessThe DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is the third most common cancer diagnosis in the world, and the second most common cause of cancer-related deaths. Despite significant progress in management strategies for colorectal cancer over the last several decades, metastatic disease remains difficult to treat and is often considered incurable. However, for patients with colorectal liver metastases (CRLM), surgical resection offers the best opportunity for survival, can be curative, and remains the gold standard. Unfortunately, surgical treatment options are underutilized. Misperceptions regarding resectable and unresectable CRLM likely play a role in this. The assessment of factors that impact resectability status like medical fitness, technical considerations, and disease biology can be difficult, necessitating careful multidisciplinary input and discussion. The identification of ideal operative time windows that align with the multimodal management of these patients can also be perplexing. For all patients with CRLM it may therefore be advantageous to obtain surgical evaluation at the time of discovering liver metastases to mitigate these challenges and minimize the risk of undertreatment. In this review we summarize current surgical management strategies for CRLM and discuss factors to be considered when determining resectability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chemotherapy is important for reducing tumor burden prior to resection and qualifying patients with potentially resectable disease for surgery, which significantly improves the likelihood of long-term survival [16].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“Improvements in precision oncology for mCRC are augmenting gains achieved through the introduction of immunotherapy [15] and improved surgical techniques that collectively are contributing toward improved long-term survival for distinct sub-types of mCRC [16].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,715 · cited 1×
“Due to the liver’s enormous regenerative capacity, as much as 80% of a healthy, noncirrhotic liver can be removed [26].”
BackgroundNordlinger, B., Sorbye, H., Glimelius, B., Poston, G. J., Schlag, P. M., Rougier, P., Bechstein, W. O., Primrose, J. N., Walpole, E. T., Finch-Jones, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60455-9 · Cited by 1,937 · cited 1×
“For patients with resectable or borderline resectable metachronous disease, treatment approaches are much simpler compared to synchronous disease: surgery alone or surgery with perioperative chemotherapy [60].”
BackgroundNordlinger, B., Guiguet, M., Vaillant, J.-C., Balladur, P., Boudjema, K., Bachellier, P., Jaeck, D., & Association Française de Chirurgie (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1254::aid-cncr5>3.0.co;2-i · Cited by 1,722
Epidemiology and Management of Liver Metastases From Colorectal Cancer
Manfredi, S., Lepage, C., Hatem, C., Coatmeur, O., Faivre, J., & Bouvier, A.-M. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000217629.94941.cf · Cited by 1,394
Wakabayashi, G., Cherqui, D., Geller, D. A., Buell, J. E., Kaneko, H., Han, H., Asbun, H. J., O’Rourke, N., Tanabe, M., Koffron, A. J., et al. (2015) · PubMed · doi:10.1097/sla.0000000000001184 · Cited by 1,336
Nordlinger, B., Sorbye, H., Glimelius, B., Poston, G. J., Schlag, P. M., Rougier, P., Bechstein, W. O., Primrose, J. N., Walpole, E. T., Finch-Jones, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70447-9 · Cited by 1,306
Clemente, C. G., Mihm, M. C., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1303::aid-cncr12>3.0.co;2-5 · Cited by 1,171
Rees, M., Tekkis, P. P., Welsh, F. K. S., O'Rourke, T., & John, T. G. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31815aa2c2 · Cited by 1,026
Two-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors
Adam, R., Laurent, A., Azoulay, D., Castaing, D., & Bismuth, H. (2000) · Annals of Surgery · doi:10.1097/00000658-200012000-00006 · Cited by 801 · cited 1×
“Use of this technique has grown exponentially since 2000, when the first series of two-stage hepatectomy in patients with unresectable bilateral CRLM was published [78].”
Karoui, M., Penna, C., Amin-Hashem, M., Mitry, E., Benoist, S., Franc, B., Rougier, P., & Nordlinger, B. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000193603.26265.c3 · Cited by 721 · cited 1×
“These impairments have the potential to impact surgical morbidity and mortality [66,67].”
BackgroundAdam, R., de Gramont, A., Figueras, J., Kokudo, N., Kunstlinger, F., Loyer, E., Poston, G., Rougier, P., Rubbia-Brandt, L., Sobrero, A., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.06.006 · Cited by 607 · cited 2×
“Colorectal metastases discovered after diagnosis or resection of the primary colorectal tumor are considered metachronous CRLM [50].”
BackgroundComplete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure?
Benoist, S., Brouquet, A., Penna, C., Julié, C., El Hajjam, M., Chagnon, S., Mitry, E., Rougier, P., & Nordlinger, B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.8727 · Cited by 607
Melendez, J. A., Arslan, V., Fischer, M. E., Wuest, D., Jarnagin, W. R., Fong, Y., & Blumgart, L. H. (1998) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(98)00240-3 · Cited by 576 · cited 1×
“, Pringle maneuver) [69], and low central venous pressure anesthesia [70].”
BackgroundEnsminger, W. D., Rosowsky, A., Raso, V., Levin, D. C., Glodé, M., Come, S. E., Steele, G. D., & Frei, E. (1978) · PubMed · Cited by 521
Pharmacologic rationale for regional drug delivery.
Collins, J. M. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.5.498 · Cited by 464 · cited 1×
“, floxuridine [FUDR]) limiting systemic toxic side effects, and allowing for the concomitant administration of systemic chemotherapy [84,85].”
BackgroundProspective Evaluation of Pringle Maneuver in Hepatectomy for Liver Tumors by a Randomized Study
Man, K., Fan, S.-T., Ng, I. O. L., Lo, C.-M., Liu, C.-L., & Wong, J. (1997) · Annals of Surgery · doi:10.1097/00000658-199712000-00007 · Cited by 444 · cited 1×
“, Pringle maneuver) [69], and low central venous pressure anesthesia [70].”
BackgroundScreening and prevention of colorectal cancer
Kanth, P., & Inadomi, J. M. (2021) · BMJ · doi:10.1136/bmj.n1855 · Cited by 358 · cited 1×
“modalities have improved [3], new systemic treatment options have lengthened survival [4], and recent developments in surgical management strategies have expanded resection eligibility criteria [5,6].”
BackgroundMentha, G., Majno, P. E., Andres, A., Rubbia-Brandt, L., Morel, P., & Roth, A. D. (2006) · British Journal of Surgery · doi:10.1002/bjs.5346 · Cited by 356 · cited 1×
“First proposed in 2006 [58], it is an appealing treatment approach as it focuses attention on the most prognostically important site of disease—the liver.”
BackgroundSelection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement
Charnsangavej, C., Clary, B., Fong, Y., Grothey, A., Pawlik, T. M., & Choti, M. A. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9023-y · Cited by 354 · cited 1×
“, at least 20% of the total estimated liver volume) [30].”
BackgroundSandström, P., Røsok, B. I., Sparrelid, E., Larsen, P. N., Larsson, A. L., Lindell, G., Schultz, N. A., Bjørnbeth, B. A., Isaksson, B., Rizell, M., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002511 · Cited by 337 · cited 1×
“When performed at experienced centers in well-selected patients, there are data that suggest it to be superior to two-stage hepatectomy [5,80].”
BackgroundTreatment sequencing in metastatic colorectal cancer
Modest, D. P., Pant, S., & Sartore-Bianchi, A. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.019 · Cited by 329 · cited 1×
“These groupings assist in determining the order of treatment strategies and sequencing [55].”
BackgroundKemeny, N. E., Melendez, F. D. H., Capanu, M., Paty, P. B., Fong, Y., Schwartz, L. H., Jarnagin, W. R., Patel, D., & D'Angelica, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1301 · Cited by 313 · cited 1×
“When systemic therapy is administered concomitantly with HAIC, objective responses as high as 85% have been observed in patients who have previously received chemotherapy [90], and as high as 100% in chemotherapy naïve patients [91].”
BackgroundParenchymal-sparing Hepatectomy in Colorectal Liver Metastasis Improves Salvageability and Survival
Mise, Y., Aloia, T. A., Brudvik, K. W., Schwarz, L., Vauthey, J.-N., & Conrad, C. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001194 · Cited by 305 · cited 1×
“Use of this technique does not increase the risk of recurrence in the liver remnant, and in fact allows for easier salvage therapy in case of liver recurrence [72].”
BackgroundBrouquet, A., Mortenson, M. M., Vauthey, J.-N., Rodriguez-Bigas, M. A., Overman, M. J., Chang, G. J., Kopetz, S., Garrett, C., Curley, S. A., & Abdalla, E. K. (2010) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2010.02.039 · Cited by 273 · cited 1×
“For patients with resectable or borderline resectable synchronous CRLM, three treatment approaches exist: classic, combined, and reversed [56].”
BackgroundDeMatteo, R. P., Palese, C., Jarnagin, W. R., Sun, R. L., Blumgart, L. H., & Fong, Y. (2000) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(00)80054-2 · Cited by 252
Creasy, J. M., Sadot, E., Koerkamp, B. G., Chou, J. F., Gonen, M., Kemeny, N. E., Balachandran, V. P., Kingham, T. P., DeMatteo, R. P., Allen, P. J., et al. (2018) · Surgery · doi:10.1016/j.surg.2018.01.004 · Cited by 243 · cited 1×
“For those who develop metastatic disease to the liver, resection of this disease is associated with a 20% cure rate [8], and five-year survival rates can exceed 50% [9].”
BackgroundKanemitsu, Y., Shimizu, Y., Mizusawa, J., Inaba, Y., Hamaguchi, T., Shida, D., Ohue, M., Komori, K., Shiomi, A., Shiozawa, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01032 · Cited by 229 · cited 5×
“Just over 75% of enrolled patients had primary colon cancer, about 45% had metachronous disease, and approximately 90% had 1–3 liver metastases [19].”
BackgroundInfluentialRobinson, S. M., Wilson, C. H., Burt, A. D., Manas, D. M., & White, S. A. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2438-8 · Cited by 228 · cited 1×
“Liver injury is regimen-specific, with oxaliplatin-based regimens often associated with sinusoidal injury and irinotecan-based regimens often associated with steatohepatitis [65].”
Bonney, G. K., Chew, C. A., Lodge, P., Hubbard, J., Halazun, K. J., Trunecka, P., Muiesan, P., Mirza, D. F., Isaac, J., Laing, R. W., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00219-3 · Cited by 187 · cited 3×
“Transplantation is not recommended for patients with BRAF V600E mutations but can be considered for patients with RAS mutations despite their poor prognostic association [83].”
BackgroundInfluentialLam, V. W. T., Spiro, C., Laurence, J. M., Johnston, E., Hollands, M. J., Pleass, H. C. C., & Richardson, A. J. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2061-0 · Cited by 186 · cited 1×
“Objective response rates for this cohort following the administration of systemic therapy alone are around 64% (range, 43–79%), generating resection rates of about 23% [89].”
BackgroundHong, N. J. L., Wright, F. C., Gagliardi, A. R., & Paszat, L. F. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21589 · Cited by 181 · cited 1×
“While it is difficult to assess a causal relationship between multidisciplinary care and improvement in patient survival [22], it has been suggested that changes in treatment recommendations for patients with gastrointestinal malignancies occur at least one third of the time after multidisciplinary evaluation [23].”
BackgroundMoulton, C.-A., Gu, C.-S., Law, C. H., Tandan, V. R., Hart, R., Quan, D., Fairfull Smith, R. J., Jalink, D. W., Husien, M., Serrano, P. E., et al. (2014) · JAMA · doi:10.1001/jama.2014.3740 · Cited by 173 · cited 1×
“CT without PET, the use of PET imaging did not frequently change surgical management or have an association with improved survival [47].”
Beppu, T., Wakabayashi, G., Hasegawa, K., Gotohda, N., Mizuguchi, T., Takahashi, Y., Hirokawa, F., Taniai, N., Watanabe, M., Katou, M., et al. (2015) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.261 · Cited by 162 · cited 1×
“Like other minimally invasive operations that have been compared to their open counterparts, minimally invasive liver resection is also often associated with lower blood loss and shorter hospital stay [100].”
BackgroundDatta, J., Narayan, R. R., Kemeny, N. E., & D'Angelica, M. I. (2019) · JAMA Surgery · doi:10.1001/jamasurg.2019.1694 · Cited by 157 · cited 1×
“For patients with initially unresectable CRLM, chemotherapy has the potential to convert such disease to resectable [48], and can be administered with or without hepatic arterial infusional chemotherapy [49].”
BackgroundVäyrynen, V, Wirta, E.-V., Seppälä, T., Sihvo, E., Mecklin, J.-P., Vasala, K., & Kellokumpu, I. (2020) · BJS Open · doi:10.1002/bjs5.50299 · Cited by 148
Khan, A. S., Garcia-Aroz, S., Ansari, M. A., Atiq, S. M., Senter-Zapata, M. J., Fowler, K. J., Doyle, M. B., & Chapman, W. C. (2018) · International Journal of Surgery · doi:10.1016/j.ijsu.2018.01.042 · Cited by 144 · cited 1×
“Current guidelines for extended hepatectomies recommend an FLR of ≥20–25% in healthy patients, >30% in patients with chemotherapy-associated liver injury, and >40% in cirrhotics [43].”
BackgroundDisappearing Colorectal Liver Metastases after Chemotherapy: Should we be Concerned?
van Vledder, M. G., Jong, M. C. D., Pawlik, T. M., Schulick, R. D., Diaz, L. A., & Choti, M. A. (2010) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-010-1348-y · Cited by 141
Osterlund, P. J., Salminen, T., Soveri, L., Kallio, R., Kellokumpu, I., Lamminmäki, A., Halonen, P., Ristamäki, R., Lantto, E., Uutela, A., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100049 · Cited by 137
Effects of systemic chemotherapy on the liver
Ramadori, G., & Cameron, S. (2010) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31651-5 · Cited by 132 · cited 1×
“Many commonly used chemotherapeutics, like 5-fluorouracil, irinotecan, and oxaliplatin are known to damage hepatocytes, and their use is often associated with the development of the aforementioned liver injuries [42].”
BackgroundLi, J., Yuan, Y., Yang, F., Wang, Y., Zhu, X., Wang, Z., Zheng, S. S., Wan, D., He, J., Wang, J., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0702-0 · Cited by 130
ALPPS Improves Survival Compared With TSH in Patients Affected of CRLM
Hasselgren, K., Røsok, B. I., Larsen, P. N., Sparrelid, E., Lindell, G., Schultz, N. A., Bjørnbeth, B. A., Isaksson, B., Larsson, A. L., Rizell, M., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003701 · Cited by 128
Morris‐Stiff, G. J., Tan, Y.-M., & Vauthey, J. (2007) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2007.07.007 · Cited by 123 · cited 1×
“These impairments have the potential to impact surgical morbidity and mortality [66,67].”
BackgroundChoi, S. H., Kim, S. Y., Park, S. H., Kim, K. W., Lee, J. Y., Lee, S. S., & Lee, M.-G. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25852 · Cited by 121 · cited 1×
“Several recent studies, however, suggest MRI to have higher sensitivity and specificity for CRLM [45,46].”
BackgroundGiuliante, F., Viganò, L., Rose, A. M. D., Mirza, D. F., Lapointe, R. W., Kaiser, G. M., Barroso, E., Ferrero, A., Isoniemi, H., López‐Ben, S., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10220-w · Cited by 121 · cited 2×
“For select patients with resectable CRLM, however, a surgery-first approach may be advantageous [17], and we have recently seen the benefit of perioperative chemotherapy come into question [18,19].”
BackgroundPak, L. M., Kemeny, N. E., Capanu, M., Chou, J. F., Boucher, T., Cercek, A., Balachandran, V. P., Kingham, T. P., Allen, P. J., DeMatteo, R. P., et al. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.24898 · Cited by 119 · cited 1×
“Rates of conversion to resectability following this combination have been reported as high as 52% [92].”
BackgroundCause of Death from Liver Metastases in Colorectal Cancer
Helling, T. S., & Martin, M. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3297-7 · Cited by 115 · cited 1×
“Despite this progress, metastatic disease remains the most common cause of death [7].”
Markers of liver regeneration—the role of growth factors and cytokines: a systematic review
Hoffmann, K., Nagel, A. J., Tanabe, K., Fuchs, J., Dehlke, K., Ghamarnejad, O., Lemekhova, A., & Mehrabi, A. (2020) · BMC Surgery · doi:10.1186/s12893-019-0664-8 · Cited by 94 · cited 1×
“A number of factors, however, like cirrhosis, fibrosis, cholestasis, steatosis, and steatohepatitis can impair the liver’s regenerative capacity [41].”
BackgroundCho, J. Y., Han, H., Wakabayashi, G., Soubrane, O., Geller, D. A., O’Rourke, N., Buell, J. F., & Cherqui, D. (2018) · Surgical Oncology · doi:10.1016/j.suronc.2017.12.003 · Cited by 79
Dueland, S., Yaqub, S., Syversveen, T., Carling, U., Hagness, M., Brudvik, K. W., & Line, P. (2021) · JAMA Surgery · doi:10.1001/jamasurg.2021.0267 · Cited by 76 · cited 2×
“modalities have improved [3], new systemic treatment options have lengthened survival [4], and recent developments in surgical management strategies have expanded resection eligibility criteria [5,6].”
BackgroundRepeat liver resection for recurrent colorectal metastases: a single‐centre, 13‐year experience
Battula, N. R., Tsapralis, D., Mayer, D. A., Isaac, J., Muiesan, P., Sutcliffe, R. P., Bramhall, S. R., Mirza, D. F., & Marudanayagam, R. (2013) · HPB · doi:10.1111/hpb.12096 · Cited by 75 · cited 2×
“that examined 969 patients who underwent hepatic resection for CRLM at a single institution over a 13-year period, repeat hepatectomy was also observed to be associated with improved long-term survival in a select cohort [96].”
BackgroundA Second Liver Resection Due to Recurrent Colorectal Liver Metastases
Cunha, A. S. (2007) · Archives of Surgery · doi:10.1001/archsurg.142.12.1144 · Cited by 75 · cited 1×
“For those who develop metastatic disease to the liver, resection of this disease is associated with a 20% cure rate [8], and five-year survival rates can exceed 50% [9].”
BackgroundTorzilli, G., Viganò, L., Cimino, M., Imai, K., Vibert, É., Donadon, M., Mansour, D. A., Castaing, D., & Adam, R. (2018) · Digestive Surgery · doi:10.1159/000486210 · Cited by 65 · cited 1×
“In select centers, outcomes are comparable to that of alternative surgical management strategies like two-stage hepatectomy (TSH) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for patients with multiple, bilobar, deeply located CRLM [74,75].”
BackgroundMao, Y., Chen, B., Wang, H., Zhang, Y., Yi, X., Liao, W., & Zhao, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-58855-1 · Cited by 63 · cited 1×
“Several recent studies, however, suggest MRI to have higher sensitivity and specificity for CRLM [45,46].”
BackgroundTorzilli, G., Serenari, M., Viganò, L., Cimino, M., Benini, C., Massani, M., Ettorre, G. M., Cescon, M., Ferrero, A., Cillo, U., et al. (2019) · HPB · doi:10.1016/j.hpb.2019.04.001 · Cited by 60 · cited 1×
“In select centers, outcomes are comparable to that of alternative surgical management strategies like two-stage hepatectomy (TSH) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for patients with multiple, bilobar, deeply located CRLM [74,75].”
BackgroundManagement of disappearing colorectal liver metastases
Kuhlmann, K. F. D., van Hilst, J., Fisher, S., & Poston, G. J. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.05.005 · Cited by 59 · cited 1×
“Operations offered to patients must be individualized with the goal of performing a complete resection of all radiographically visible disease (including disappearing liver metastases given the risk of recurrence) [36,38], maximizing FLR, and preserving vascular inflow, outflow, and biliary drainage.”
BackgroundSurgical Referral for Colorectal Liver Metastases: A Population-Based Survey
Krell, R. W., Reames, B. N., Hendren, S. K., Frankel, T. L., Pawlik, T. M., Chung, M. H., Kwon, D., & Wong, S. L. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4318-x · Cited by 58 · cited 2×
“Unfortunately, surgical management strategies for colorectal liver metastases (CRLM) remain underutilized [10].”
BackgroundOxenberg, J. C., Papenfuss, W. A., Esemuede, I. O., Attwood, K. M., Simunovic, M. R. I., Kuvshinoff, B. W., & Francescutti, V. A. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4163-y · Cited by 57 · cited 1×
“While it is difficult to assess a causal relationship between multidisciplinary care and improvement in patient survival [22], it has been suggested that changes in treatment recommendations for patients with gastrointestinal malignancies occur at least one third of the time after multidisciplinary evaluation [23].”
BackgroundOba, A., Mise, Y., Ito, H., Hiratsuka, M., Inoue, Y., Ishizawa, T., Arita, J., Matsueda, K., Takahashi, Y., & Saiura, A. (2018) · HPB · doi:10.1016/j.hpb.2018.02.377 · Cited by 57
Choti, M. A., Thomas, M., Wong, S. L., Eaddy, M. T., Pawlik, T. M., Hirose, K., Weiss, M. J., Kish, J., & Green, M. R. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4925-1 · Cited by 56
Sutherland, F. R., & Harris, J. D. (2002) · Archives of Surgery · doi:10.1001/archsurg.137.11.1305 · Cited by 52
Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception
Saltz, L. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.6198 · Cited by 50 · cited 1×
“Benefits in DFS and PFS for patients are not insignificant, but they can easily be misperceived as benefits in overall survival [62].”
BackgroundRole of intra‐arterial hepatic chemotherapy in the treatment of colorectal cancer metastases
Kingham, T. P., D'Angelica, M. I., & Kemeny, N. E. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21753 · Cited by 48 · cited 1×
“Traditionally, however, it has often been used as a strategy to convert patients with initially unresectable CRLM to resectable [88].”
Dijkstra, M., Nieuwenhuizen, S., Puijk, R. S., Timmer, F. E. F., Geboers, B., Schouten, E. A. C., Opperman, J., Scheffer, H. J., de Vries, J. J. J., Versteeg, K. S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9080962 · Cited by 48 · cited 1×
“, rate of disease progression, suspicion of extrahepatic disease, timing of appearance with relationship to the primary colorectal tumor, primary colorectal tumor sidedness, RAS/BRAF mutation status, microsatellite instability [MSI] status) [28,29], and technical aspects like relationship to vascular inflow, outflow,…”
BackgroundPractical questions in liver metastases of colorectal cancer: general principles of treatment
González, H. D., & Figueras, J. (2007) · HPB · doi:10.1080/13651820701457992 · Cited by 46
Homayounfar, K., Bleckmann, A., Helms, H., Lordick, F., Rüschoff, J., Conradi, L., Sprenger, T., Ghadimi, M. B., & Liersch, T. (2014) · British journal of surgery · doi:10.1002/bjs.9436 · Cited by 46
Mohammad, W. M., Martel, G., Mimeault, R., Fairfull-Smith, R. J., Auer, R. C., & Balaa, F. K. (2012) · HPB · doi:10.1111/j.1477-2574.2012.00440.x · Cited by 44 · cited 1×
“, rate of disease progression, suspicion of extrahepatic disease, timing of appearance with relationship to the primary colorectal tumor, primary colorectal tumor sidedness, RAS/BRAF mutation status, microsatellite instability [MSI] status) [28,29], and technical aspects like relationship to vascular inflow, outflow,…”
BackgroundRobotic surgery for colorectal liver metastases resection: A systematic review
Rocca, A., Scacchi, A., Cappuccio, M., Avella, P., Bugiantella, W., Rosa, M. D., Costa, G., Polistena, A., Pisanelli, M. C., Amato, B., et al. (2021) · International Journal of Medical Robotics and Computer Assisted Surgery · doi:10.1002/rcs.2330 · Cited by 43
Tani, K., Shindoh, J., Akamatsu, N., Arita, J., Kaneko, J., Sakamoto, Y., Hasegawa, K., & Kokudo, N. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24805 · Cited by 40
Andreou, A., Gloor, S., Inglin, J., Martinelli, C. D. P., Banz, V. M., Lachenmayer, A., Kim‐Fuchs, C., Candinas, D., & Beldi, G. (2021) · Surgical Oncology · doi:10.1016/j.suronc.2021.101631 · Cited by 38 · cited 3×
“Historically, on -stage hepatectomy for patients with CRLM was considered superior to parenchym l-sparing hepatectomy [76], but several studies have now shown par nchymal-sparing techniques to be oncologically equivalent and associated with lower morbidity and mortality [71,77].”
MethodHsu, H., Wu, L., Lin, P., Juan, C.-H., Huang, Y.-Y., Chou, P., & Chen, J. (2020) · Medicine · doi:10.1097/md.0000000000019029 · Cited by 37 · cited 1×
“One well-recognized phenomenon, for instance, is that of chemotherapy-induced peripheral neuropathy, which can substantially affect quality of life [61].”
BackgroundBuisman, F. E., Filipe, W. F., Galjart, B., Grünhagen, D. J., Homs, M. Y. V., Moelker, A. D., Verhoef, C. K., & Koerkamp, B. G. (2021) · HPB · doi:10.1016/j.hpb.2021.10.014 · Cited by 36 · cited 1×
“While it is not a liver resection strategy, it can be placed following hepatectomy for adjuvant liver-directed chemotherapy [86,87].”
BackgroundResection and local therapy for liver metastases
Schlag, P. M., Benhidjeb, T., & Stroszczynski, C. (2002) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2002.0286 · Cited by 35
Role of Repeated Hepatectomy in the Multimodal Treatment of Hepatic Colorectal Metastases
Ahmad, A. (2007) · Archives of Surgery · doi:10.1001/archsurg.142.6.526 · Cited by 35 · cited 1×
“For select patients, repeat hepatectomy is associated with improved OS if there is a sufficient remnant of healthy liver tissue [95,96].”
BackgroundAssessing the optimal duration of chemotherapy in patients with colorectal liver metastases
White, R. R., Schwartz, L. H., Munoz, J. A., Raggio, G. A., Jarnagin, W. R., Fong, Y., D'Angelica, M. I., & Kemeny, N. E. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.21042 · Cited by 33 · cited 2×
“In one single institution study, it was observed that for patients treated with chemotherapy alone or HAIC combined with systemic chemotherapy, additional tumor response was not appreciated beyond 4 months in either group [63].”
BackgroundTang, H., Li, B., Zhang, H., Dong, J., & Lu, W. (2016) · Scientific Reports · doi:10.1038/srep32304 · Cited by 33 · cited 1×
“Historically, on -stage hepatectomy for patients with CRLM was considered superior to parenchym l-sparing hepatectomy [76], but several studies have now shown par nchymal-sparing techniques to be oncologically equivalent and associated with lower morbidity and mortality [71,77].”
Ceccarelli, G., Rocca, A., Rosa, M. D., Fontani, A., Ermili, F., Andolfi, E., Bugiantella, W., & Sandri, G. B. L. (2021) · Updates in Surgery · doi:10.1007/s13304-021-01009-3 · Cited by 33
Synchronous and metachronous liver metastases in patients with colorectal cancer.
Okholm, C., Mollerup, T. K., Schultz, N. A., Strandby, R. B., & Achiam, M. P. (2018) · PubMed · Cited by 32
Jong, M. C. D., Beckers, R. C. J., van Woerden, V., Sijmons, J., Bemelmans, M. H. A., van Dam, R. M., & Dejong, C. H. C. (2018) · HPB · doi:10.1016/j.hpb.2018.01.005 · Cited by 31
Two-Stage Hepatectomy for Bilateral Colorectal Liver Metastases: A Multi-institutional Analysis
Chavez, M. I., Gholami, S., Kim, B. J., Margonis, G. A., Ethun, C. G., Tsai, S., Christians, K. K., Clarke, C. N., Mogal, H., Maithel, S. K., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09459-6 · Cited by 30 · cited 2×
“Results from the largest two-stage hepatectomy series in the US, published in 2021, demonstrate it to be a safe and feasible procedure for patients with bilobar disease [79].”
BackgroundQuestioning Why More Patients With Colorectal Liver Metastases Are Not Referred for Metastasectomy
Wei, A. C.-C., & Jarnagin, W. R. (2020) · JAMA Surgery · doi:10.1001/jamasurg.2020.1460 · Cited by 28 · cited 1×
“To facilitate optimal management all patients with CRLM should have a surgical evaluation at the time of liver metastasis discovery, prior to any treatment decision [14,15], and preferably in the setting of a multidisciplinary conference [16].”
Conversion therapy in patients with colorectal liver metastases
Villard, C., Habib, M., Nordenvall, C. A. M., Nilsson, P. J., Jorns, C., & Sparrelid, E. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.02.019 · Cited by 28 · cited 1×
“For patients with initially unresectable CRLM, chemotherapy has the potential to convert such disease to resectable [48], and can be administered with or without hepatic arterial infusional chemotherapy [49].”
BackgroundLocoregional Therapies for Colorectal Cancer Liver Metastases: Options Beyond Resection
Uhlig, J., Lukovic, J., Dawson, L. A., Patel, R. A., Cavnar, M. J., & Kim, H. S. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320519 · Cited by 27 · cited 1×
“Additionally, there are numerous locoregional therapies for which all patients with CRLM, including those with extrahepatic disease, should be considered [20,21].”
BackgroundLiver-directed therapy in metastatic colorectal cancer
Kelly, C. M., & Kemeny, N. E. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1345629 · Cited by 25 · cited 1×
“When systemic therapy is administered concomitantly with HAIC, objective responses as high as 85% have been observed in patients who have previously received chemotherapy [90], and as high as 100% in chemotherapy naïve patients [91].”
BackgroundGavriilidis, P., Katsanos, K. H., Sutcliffe, R. P., Simopoulos, C. E., Azoulay, D., & Roberts, K. J. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3887 · Cited by 25
Chen, Q., Li, X., Zhao, J., Bi, X., Li, Z., Huang, Z., Zhang, Y., Zhou, J., Zhao, H., & Cai, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4289 · Cited by 23 · cited 1×
“Similar findings were observed in another single-institutional study that examined 407 patients with CRLM who underwent hepatectomy after neoadjuvant chemotherapy [64].”
ResultLiver transplantation for colorectal liver metastasis
Simoneau, È., D'Angelica, M. I., & Halazun, K. J. (2019) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000623 · Cited by 22 · cited 2×
“The global transplant community continues to face a shortage of organs [82], and current indications for OLT for patients with CRLM are not well-defined [81].”
BackgroundHellingman, T., de Swart, M. E., Joosten, J. J. A., Meijerink, M. R., de Vries, J. J. J., de Waard, J. W. D., van Zweeden, A. A., Zonderhuis, B. M., & Geert Kazemier, M. (2020) · Surgical Oncology · doi:10.1016/j.suronc.2020.09.024 · Cited by 21 · cited 2×
“For patients with CRLM, it is speculated that at least 20% of patients with isolated liver metastases who have been advised to undergo a chemotherapy-first approach may instead be eligible for upfront surgery [16].”
BackgroundBuisman, F. E., Filipe, W. F., Kemeny, N. E., Narayan, R. R., Srouji, R. M., Balachandran, V. P., Boerner, T., Drebin, J. A., Jarnagin, W. R., Kingham, T. P., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08776-0 · Cited by 20 · cited 3×
“), and chemotherapyadministering teams must know how to properly access the pump, troubleshoot malfunctions, and manage toxicities associated with combined HAIC and systemic chemotherapy [86,93,94].”
BackgroundDebulking surgery for colorectal liver metastases: Foolish or chance?
Adam, R. A., Kitano, Y., Abdelrafee, A., Allard, M., & Baba, H. (2020) · Surgical Oncology · doi:10.1016/j.suronc.2020.02.008 · Cited by 19
Araújo, R. L. C., Milani, J. M., Armentano, D. P., Moreira, R. B., Pinto, G. S. F., de Castro, L. A., & Lucchesi, F. R. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25784 · Cited by 18
Wong, L. H., Sutton, T. L., Walker, B. S., Lopez, C. D., Kardosh, A., Eil, R. L., Chen, E. Y.-S., Billingsley, K. G., & Mayo, S. C. (2021) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2021.03.007 · Cited by 18 · cited 1×
“Some centers employ extreme parenchymal-sparing techniques as repeat hepatectomy for recurrent CRLM can be safely performed in select patients [73].”
BackgroundJo, H.-S., Kim, D., Jung, S.-W., Yu, Y., Choi, S.-B., Kim, W., Han, H. J., & Song, T.-J. (2018) · Annals of Hepato-Biliary-Pancreatic Surgery · doi:10.14701/ahbps.2018.22.2.93 · Cited by 14 · cited 1×
“In this regard, surgical planning revolves around strategizing for the full removal of the tumor while preserving a sufficient remnant of healthy liver tissue (future liver remnant [FLR]) to limit the risk of postoperative liver dysfunction/failure [34].”
BackgroundChaudhry, S., Fields, R. C., Grierson, P. M., & Lim, K. (2021) · Cancers · doi:10.3390/cancers13061283 · Cited by 14 · cited 2×
“), and chemotherapyadministering teams must know how to properly access the pump, troubleshoot malfunctions, and manage toxicities associated with combined HAIC and systemic chemotherapy [86,93,94].”
BackgroundPerioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates
Lee, H. Y., & Woo, I. S. (2021) · Cancers · doi:10.3390/cancers13184590 · Cited by 14
ASCO 2016 – update colorectal liver metastases
Kaczirek, K. (2017) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-016-0308-y · Cited by 12 · cited 1×
“, numerous liver metastases, evidence of disease progression, possible extrahepatic disease) [31].”
BackgroundColorectal Liver Metastases: A Changing Treatment Landscape
Brudvik, K. W., Passot, G., & Vauthey, J. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.009746 · Cited by 9 · cited 1×
“, rate of disease progression, suspicion of extrahepatic disease, timing of appearance with relationship to the primary colorectal tumor, primary colorectal tumor sidedness, RAS/BRAF mutation status, microsatellite instability [MSI] status) [28,29], and technical aspects like relationship to vascular inflow, outflow,…”
BackgroundCurrent status of left lobe adult to adult living donor liver transplantation
Braun, H. J., & Roberts, J. P. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000863 · Cited by 8 · cited 1×
“The global transplant community continues to face a shortage of organs [82], and current indications for OLT for patients with CRLM are not well-defined [81].”
BackgroundMetastatic Colorectal Cancer to the Liver: Involve the Surgeon Early and Often
D'Angelica, M. I., & Kemeny, N. E. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4456-9 · Cited by 5 · cited 1×
“To facilitate optimal management all patients with CRLM should have a surgical evaluation at the time of liver metastasis discovery, prior to any treatment decision [14,15], and preferably in the setting of a multidisciplinary conference [16].”
Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma
Yamasaki, T., Saeki, I., Yamauchi, Y., Sasaki, R., Tanabe, N., Oono, T., Matsuda, T., Hisanaga, T., Matsumoto, T., Hidaka, I., et al. (2021) · Applied Sciences · doi:10.3390/app11041882 · Cited by 3 · cited 2×
“), and chemotherapyadministering teams must know how to properly access the pump, troubleshoot malfunctions, and manage toxicities associated with combined HAIC and systemic chemotherapy [86,93,94].”
Background
Research works printed but not linked: 1
- Jarnagin, W.R., Belghiti, J., and Blumgart, L.H. (2017). Blumgart’s Surgery for the Liver, Biliary Tract, and Pancreas, Elsevier Saunders. [6th ed.].
Cited by
Colorectal Cancer: Current Updates and Future Perspectives
Marcellinaro, R., Spoletini, D., Grieco, M., Avella, P., Cappuccio, M., Troiano, R., Lisi, G., Garbarino, G. M., & Carlini, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010040 · Cited by 173
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
Wang, K., Liu, Y., Hao, M., Li, H., Liang, X., Yuan, D., & Ding, L. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03127-1 · Cited by 22
“Nearly 20% of postoperative patients would survive for more than 10 years [3].”
BackgroundLiang, M., Ma, X., Wang, L., Li, D., Wang, S., Zhang, H., & Zhao, X. (2022) · Cancer Imaging · doi:10.1186/s40644-022-00485-z · Cited by 15
Mkabaah, L. B., Davey, M. G., Kerin, E. P., Ryan, O. K., Ryan, É. J., Donnelly, M., Ahmed, O., McEntee, G., Conneely, J. B., & Donlon, N. E. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27909 · Cited by 15
“Never-theless, OLR remains the surgical approach of choice for more challenging cases, with some surgical centres lacking accessibility to newer minimally invasive approaches [11, 12].”
Metadata
- Authors
- Ivey, G. D., Johnston, F. M., Azad, N. S., Christenson, E. S., Lafaro, K. J., & Shubert, C. R.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Shubert, Christopher R.
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-02-20
- Volume
- 14
- Issue
- 4
- Pages
- 1063
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8870224
- OpenAlex
- W4213229077
- Cited by
- 70
- References
- 99
- Citations by year
- 2026: 14 · 2025: 19 · 2024: 14 · 2023: 18 · 2022: 5
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- colorectal cancer, liver metastasis, surgical resection, resectability assessment, multimodal therapy, operative timing, medical fitness, multidisciplinary assessment, undertreatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.